Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer’s disease diagnosis

[1] Wu Y-T(2016)Dementia in western Europe: epidemiological evidence and implications for policy making Lancet Neurol 15 116-124

[2] Fratiglioni L(2011)Epidemiology of Alzheimer disease Nat Rev Neurol 7 137-387

[3] Matthews FE(2016)Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease Ann Neurol 80 379-663

[4] Lobo A(2018)Biomarkers for Alzheimer's disease: current status and prospects for the future J Intern Med 284 643-629

[5] Breteler MM(2014)Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol 13 614-607

[6] Skoog I(2010)Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall Clin Chem Lab Med 48 603-240

[7] Brayne C(2009)A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Ann Clin Biochem 46 235-15

[8] Reitz C(2015)Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability Clin Chim Acta 449 9-430

[9] Brayne C(2012)Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update Biomark Med 6 419-2066

[10] Mayeux R(2018)Commutability of the certified reference materials for the standardization of β-amyloid 1–42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1–40 measurements Clin Chem Lab Med 56 2058-269

[1] Wu Y-T(2016)Dementia in western Europe: epidemiological evidence and implications for policy making Lancet Neurol 15 116-124

[2] Fratiglioni L(2011)Epidemiology of Alzheimer disease Nat Rev Neurol 7 137-387

[3] Matthews FE(2016)Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease Ann Neurol 80 379-663

[4] Lobo A(2018)Biomarkers for Alzheimer's disease: current status and prospects for the future J Intern Med 284 643-629

[5] Breteler MM(2014)Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol 13 614-607

[6] Skoog I(2010)Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall Clin Chem Lab Med 48 603-240

[7] Brayne C(2009)A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Ann Clin Biochem 46 235-15

[8] Reitz C(2015)Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability Clin Chim Acta 449 9-430

[9] Brayne C(2012)Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update Biomark Med 6 419-2066

[10] Mayeux R(2018)Commutability of the certified reference materials for the standardization of β-amyloid 1–42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1–40 measurements Clin Chem Lab Med 56 2058-269